U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Aline de Conti
  1. Science & Research (NCTR)

Aline de Conti Ph.D.
Leadership Role

Staff Fellow — Division of Biochemical Toxicology

Aline de Conti, Ph.D.
Aline de Conti, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigator page


About  |  Publications | Lab Members


Background

Dr. Aline de Conti received a graduate degree in industrial pharmacy from the Oswaldo Cruz College in Sao Paulo, Brazil in 2005, and a Ph.D. degree in food sciences from the University of Sao Paulo, Sao Paulo, Brazil in 2009. During 2009-2012, Dr. de Conti conducted postdoctoral research on nutrition and cancer at University of Sao Paulo, including six months as a visiting researcher at NCTR’s Division of Biochemical Toxicology. In 2012, Dr. de Conti joined NCTR as postdoctoral fellow and in 2015 she was converted to an FDA staff fellow. 

Dr. de Conti has published more than 40 research articles and two book chapters, and has served as a reviewer for more than 30 scientific articles. In 2018, she received the NCTR Scientific Achievement Award as Outstanding Junior Investigator and the NCTR Director’s Award for providing outstanding service to NCTR/FDA. She has been invited to be a member of a working group for International Agency for Cancer Research to evaluate carcinogenic risks to humans. 
 

Research Interests

Dr. de Conti’s research interests are related to the identification of molecular mechanisms of carcinogenesis, with a focus on the role of epigenetic alterations. Dr. de Conti has investigated the role of epigenetic alterations in liver carcinogenesis induced by several non-genotoxic and genotoxic carcinogens. The results of Dr. de Conti’s research demonstrate the importance of epigenetic alterations as contributing factors to carcinogenesis and indicate that epigenetic alterations may represent a class of biomarkers with a great potential for the identification of exposure status, damage response, and/or disease state, and may become an essential tool for hazard identification. Another major area of Dr. de Conti’s research has been investigating the genomic and epigenomic drivers of nonalcoholic fatty liver disease (NAFLD) and NAFLD-associated liver cancer. Currently, NAFLD is the most prevalent form of chronic liver disease in the United States and other countries worldwide, affecting approximately one-quarter of the world's population.  Using in vivo models of NAFLD-related hepatocarcinogenesis, Dr. de Conti demonstrated the significance of epigenetic abnormalities, including alterations in histone modifications, DNA methylation, and chromatin structure, in the development of NAFLD-related HCC.  In addition, Dr. de Conti is interested in the elucidation of chemopreventive bioactive food components against liver carcinogenesis, including farnesol, β-ionone, tributyrin, and folic acid, as well as, in the investigation of the mechanisms of action involved in the prevention of liver cancer.

Professional Societies/National and International Groups 

Society of Toxicology
Member
2013 – Present 

Hispanic Organization of Toxicologists Special Interest Group of the Society of Toxicology
Vice-President
2020 – 2021

Carcinogenesis Section Specialty Group of the Society of Toxicology
Member
2019 – Present

 

Selected Publications

Characterization of the Variability in the Extent of Nonalcoholic Fatty Liver Induced by a High-Fat Diet in the Genetically Diverse Collaborative Cross Mouse Model.
de Conti A., Tryndyak V., Willett R.A., Borowa-Mazgaj B., Watson A., Patton R., Khare S., Muskhelishvili L., Olson G.R., Avigan M.I., Cerniglia C.E., Ross S.A., Sanyal A.J., Beland F.A., Rusyn I., and Pogribny I.P.
FASEB J. 2020, 34(6):7773-7785, doi:10.1096/fj.202000194R [Epub 2020, Apr 18].

Gene Expression and DNA Methylation Alterations During Non-Alcoholic Steatohepatitis-Associated Liver Carcinogenesis.
Dreval K., Tryndyak V., de Conti A., Beland F.A., and Pogribny I.P.
Front Genet. 2019, 10:486, doi:10.3389/fgene.2019.00486. eCollection 2019.

Genotoxic and Epigenotoxic Alterations in the Lung and Liver of Mice Induced by Acrylamide: a 28 Day Drinking Water Study.
de Conti A., Tryndyak V., VonTungeln L.S., Churchwell M.I., Beland F.A., Antunes A.M.M., and Pogribny I.P.
Chem Res Toxicol. 2019, 32(5):869-877, doi:10.1021/acs.chemrestox.9b00020. [Epub 2019, Mar 12].

Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.
Borowa-Mazgaj B., de Conti A.,Tryndyak V., Steward C.R., Jimenez L., Melnyk S., Seneshaw M., Mirshahi F., Rusyn I., Beland F.A., Sanyal A.J., and Pogribny I.P.
Toxicol Sci. 2019, 170(2):273-282, doi:10.1093/toxsci/kfz110.

Population-Based Analysis of DNA Damage and Epigenetic Effects of 1,3-butadiene in the Mouse.
Lewis L., Borowa-Mazgaj B., de Conti A., Chappell G.A., Luo Y.S., Bodnar W., Konganti K., Wright F.A., Threadgill D.W., Chiu W.A., Pogribny I.P., and Rusyn I.
Chem Res Toxicol. 2019, 32(5):887-898, doi:10.1021/acs.chemrestox.9b00035. [Epub 2019, Apr 25].

Identification of Chromatin-Accessible Domains in Non-Alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.
Dechassa M.L., Tryndyak V., de Conti A., Xiao W., Beland F.A., and Pogribny I.P.
Mol Carcinog. 2018, 57(8):978-987, doi:10.1002/mc.22818. [Epub 2018, Apr 16].

Furan-Induced Transcriptomic and Gene-Specific DNA Methylation Changes in the Livers of Fischer 344 Rats in a 2-year Carcinogenicity Study.
Tryndyak V., de Conti A., Doerge D.R., Olson G.R., Beland F.A., and Pogribny I.P.
Arch Toxicol. 2017, 91(3):1233-1243, doi:10.1007/s00204-016-1786-8. [Epub 2016, Jul 7].

Mir-1247 Blocks SOX9-Mediated Regeneration in Alcohol- and Fibrosis-Associated Acute Kidney Injury in Mice.
Dreval K., de Conti A., Furuya S., Beland F.A., Rusyn I., and Pogribny I.P.
Toxicology. 2017, 384:40-49, doi:10.1016/j.tox.2017.03.004. [Epub 2017, Mar 8].

Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis is Associated with Histone H4 lysine 16 deacetylation.
de Conti A., Dreval K., Tryndyak V., Orisakwe O.E., Ross S.A., Beland F.A., and Pogribny I.P.
Mol Cancer Res. 2017, 15(9):1163-1172, doi:10.1158/1541-7786.MCR-17-0109. [Epub 2017, May 16].

The Role of Epigenomic Alterations in Furan-Induced Hepatobiliary Pathologies.
de Conti A., Beland F.A., and Pogribny I.P.
Food Chem Toxicol. 2017, 109(Pt 1):677-682, doi:10.1016/j.fct.2017.07.049. [Epub 2017, Jul 26].

Irreversible Down-Regulation of mir-375 in the Livers of Fischer 344 Rats After Chronic Furan Exposure.
de Conti A., Tryndyak V., Doerge D.R., Beland F.A., and Pogribny I.P.
Food Chem Toxicol. 2016, 98(Pt A):2-10, doi:10.1016/j.fct.2016.06.027. [Epub 2016, Jun 28].

New Insights Into The Molecular Mechanisms of Chemical Carcinogenesis: in vivo Adduction of Histone H2B by a Reactive Metabolite of the Chemical Carcinogen Furan.
Nunes J., Martins I.L., Charneira C., Pogribny I.P., de Conti A., Beland F.A., Marques M.M., Jacob C.C., and Antunes A.M.M.
Toxicol Lett. 2016, 264:106-113, doi:10.1016/j.toxlet.2016.10.018. [Epub 2016, Nov 5].

Persistence of Furan-Induced Epigenetic Aberrations in the Livers of F344 Rats.
de Conti A., Kobets T., Tryndyak V., Burnett S.D., Han T., Fuscoe J.C., Beland F.A., Doerge D.R., and Pogribny I.P.
Toxicol Sci. 2015, 144(2):217-26, doi:10.1093/toxsci/kfu313. [Epub 2014, Dec 23].

Irreversible Down-Regulation of Mir-375 in the Livers of Fischer 344 Rats after Chronic Furan Exposure.
de Conti A., Tryndyak V., Doerge D.R., Beland F.A., and Pogribny I.P.
Food Chem Toxicol. 2016, 98(Pt A):2-10, doi:10.1016/j.fct.2016.06.027. [Epub 2016, Jun 28].

Strain-Dependent Dysregulation of One-Carbon Metabolism in Male Mice is Associated With Choline- and Folate-Deficient Diet-Induced Liver Injury.
Pogribny I.P., Kutanzi K., Melnyk S., de Conti A., Tryndyak V., Montgomery B., Pogribna M., Muskhelishvili L., Latendresse J.R., James S.J., Beland F.A., and Rusyn I.
FASEB J. 2013, 27(6):2233-43, doi:10.1096/fj.12-227116. [Epub 2013, Feb 25].

The Chemopreventive Activity of the Butyric Acid Prodrug Tributyrin in Experimental Rat Hepatocarcinogenesis is Associated with p53 Acetylation and Activation of the p53 Apoptotic Signaling Pathway.
de Conti A., Tryndyak V., Koturbash I., Heidor R., Kuroiwa-Trzmielina J., Ong T.P., Beland F.A., Moreno F.S., and Pogribny I.P.
Carcinogenesis. 2013, 34(8):1900-6, doi:10.1093/carcin/bgt124. [Epub 2013, Apr 8].

Chemopreventive Effects of the Dietary Histone Deacetylase Inhibitor Tributyrin Alone or in Combination with Vitamin A During the Promotion Phase of Rat Hepatocarcinogenesis.
de Conti A., Kuroiwa-Trzmielina J., Horst M.A., Bassoli B.K., Chagas C.E., Purgatto E., Cavalher F.P., Camargo A.A., Jordão A.A. Jr., Vannucchi H., Scolastici C., Ong T.P., and Moreno F.S.
J Nutr Biochem. 2012, 23(8):860-6, doi:10.1016/j.jnutbio.2011.04.010. [Epub 2011, Sep 21].

Interstrain Differences in the Severity of LInjury Induced by a Choline- and Folate-Deficient Diet in Mice are Associated with Dysregulation of Genes Involved in Lipid Metabolism.
Tryndyak V., de Conti A., Kobets T., Kutanzi K., Koturbash I., Han T., Fuscoe J.C., Latendresse J.R., Melnyk S., Shymonyak S., Collins L., Ross S.A., Rusyn I., Beland F.A., and Pogribny I.P.
FASEB J. 2012, 26(11):4592-602, doi:10.1096/fj.12-209569. [Epub 2012, Aug 7].

Chemoprevention of Rat Hepatocarcinogenesis with Histone Deacetylase Inhibitors: Efficacy of Tributyrin, a Butyric Acid Prodrug.
Kuroiwa-Trzmielina J., de Conti A., Scolastici C., Pereira D., Horst M.A., Purgatto E., Ong T.P., and Moreno F.S.
Int J Cancer. 2009, 124(11):2520-7, doi:10.1002/ijc.24212.

Geranylgeraniol and Beta-Ionone Inhibit Hepatic Preneoplastic Lesions, Cell Proliferation, Total Plasma Cholesterol and DNA Damage During the Initial Phases of Hepatocarcinogenesis, But Only the Former Inhibits NF-kappaB Activation.
de Moura Espíndola R., Mazzantini R.P., Ong T.P., de Conti A., Heidor R., and Moreno F.S.
Carcinogenesis. 2005, 26(6):1091-9, doi:10.1093/carcin/bgi047. [Epub 2005, Feb 17].

 

Lab Members

Contact Information for all lab members:
(870) 543-7121
NCTRResearch@fda.hhs.gov 

Igor Pogribny, M.D., Ph.D. 
Research Biologist

Volodymyr Tryndyak, Ph.D.
Senior Staff Fellow

Barbara Borowa-Mazgaj, Ph.D.
ORISE Postdoctoral Fellow

Rose Willett, Ph.D.
ORISE Postdoctoral Fellow


Contact Information
Aline de Conti
(870)543-7121
Back to Top